Brendan Teehan - 01 Feb 2025 Form 4 Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Chief Commercial Officer
Signature: /s/ Kristen Williams, Attorney-in-Fact
Issuer symbol: PCRX
Transactions as of: 01 Feb 2025
Transactions value $: $2,645,705
Form type: 4
Filing time: 04 Feb 2025, 18:25:33 UTC
Previous filing: 28 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCRX	Common Stock	Award	$0	+54K		$0.00	54K	01 Feb 2025	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PCRX	Stock Option (Right to Buy)	Award	$2.65M	+99.5K		$26.59	99.5K	04 Feb 2025	Common Stock	99.5K	$26.59	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents restricted stock units that vest in four equal annual installments beginning on February 1, 2026, provided that the reporting person remains in continuous service with the issuer as of each vesting date. Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F2	The stock option vests and becomes exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date.